2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-162972
    PROTAC PD-L1 degrader-2 2995357-09-8
    PROTAC PD-L1 degrader-2 is a PD-L1 PROTAC degrader with an IC50 of 197.4 nM and a Kd of 301 nM. PROTAC PD-L1 degrader-2 induces PD-L1 endocytosis, drives degradation via the proteasomal and lysosomal pathways, and inhibits the PD-1/PD-L1 interaction. As an immune activator, PROTAC PD-L1 degrader-2 increases the levels of CD4+, CD8+, granzyme B and perforin. PROTAC PD-L1 degrader-2 can be used in studies related to colon cancer immunology.
    PROTAC PD-L1 degrader-2
  • HY-163039
    DOTA-biotin 188428-79-7 98%
    DOTA-biotin is a DOTA-based small molecule hapten. DOTA-biotin has low tissue and whole-body retention in mice 4 h postinjection.
    DOTA-biotin
  • HY-164826
    Acetyl zingerone 30881-23-3 99.34%
    Acetyl zingerone is an analog of Zingerone (HY-14621). Acetyl zingerone downregulates the expression of ROS metabolism-related genes, fibroblast senescence-related genes, keratinocyte differentiation-related genes, and IL-17A target genes. Acetyl zingerone inhibits the activities of MMP-1, MMP-3, and MMP-12, as well as the activation of NLRP3 inflammasome, pyroptosis (pyroptosis), ferroptosis (ferroptosis), cartilage destruction, and UVA-induced cyclobutane pyrimidine dimer formation. Acetyl zingerone upregulates the expression of collagen, proteoglycan, extracellular matrix glycoprotein, Notch pathway, and GPX4 gene, activates Nrf2 and HO-1, induces extracellular matrix synthesis and PINK1/Parkin-mediated mitophagy (mitophagy), and promotes chondrocyte survival. Acetyl zingerone alleviates the progression of osteoarthritis in mice. Acetyl zingerone can be used in research related to skin aging, inflammatory skin diseases, osteoarthritis, melanoma, and non-melanoma skin cancer.
    Acetyl zingerone
  • HY-164853
    Kanglexin 2228847-12-7 99.65%
    Kanglexin is an orally active and novel anthraquinone compound. Kanglexin inhibits NLRP3 inflammatory body activation and cell pyroptosis, and has a cardioprotective effect. Kanglexin promotes angiogenesis through FGFR1/ERK signaling pathway and accelerates diabetic wound healing. In addition, Kanglexin has the effect of lipid-lowering and inhibiting the dedifferentiation of vascular smooth muscle cells, and can be used in the study of hyperlipidemia, fatty liver and atherosclerosis.
    Kanglexin
  • HY-168376
    9(10)-Nitrooleate 1092676-99-7 99.0%
    9 (10)-Nitrooleate (9(10)-Nitrated oleic acid) is an endogenous lipid signaling mediator with vasoprotective effects. 9 (10)-Nitrooleate enhances enzymatic activity and improves nitric oxide bioavailability by inducing phosphorylation of Akt and ERK1/2, regulating the multi-site phosphorylation status of eNOS and optimizing its interaction with Hsp90. 9 (10)-Nitrooleate also activates PPARα, PPARδ and PPARγ receptors, thereby regulating adipogenesis, glucose uptake and inflammation-related gene expression, and exhibits immunosuppressive effects by inhibiting neutrophil migration and cytokine secretion. 9 (10)-Nitrooleate is widely used in studies of sepsis and related inflammatory diseases.
    9(10)-Nitrooleate
  • HY-168981
    Larubrilstat 2765226-31-9 98.89%
    Larubrilstat is a vascular non-inflammatory molecule-1 (VNN1) inhibitor.
    Larubrilstat
  • HY-169004
    CBT-295 1623794-90-0 99.34%
    CBT-295 is an orally active autotaxin (ATX) inhibitor. CBT-295 exhibits a significant reduction in inflammatory cytokines like TGF-β, TNF-α and IL-6 levels, also reduced bile duct proliferation marker CK-19 and lowered liver fibrosis. The reversal of liver fibrosis with CBT-295 led to a reduction in blood and brain ammonia levels. CBT-295 also reduced neuroinflammation induced by ammonia. CBT-295 is promising for research of liver cirrhosis and associated encephalopathy.
    CBT-295
  • HY-169402
    PDE1-IN-9 2982945-41-3 98%
    PDE1-IN-9 (Compound 7a) is a selective inhibitor for phosphodiesterase 1 (PDE1), that inhibits PDE1C with an IC50 of 11 nM. PDE1-IN-9 reduces mRNA expression of IL-1β, IL-6, TNF-α and iNOS, inhibits the production of nitric oxide (NO) and reactive oxygen species (ROS). PDE1-IN-9 exhibits good metabolic stability in rat liver microsomes.
    PDE1-IN-9
  • HY-169703
    SPA0355 1251839-15-2 99.54%
    SPA0355 is a thiourea derivative that has antioxidant and anti-inflammatory properties. SPA0355 inhibits the RANKL (receptor activator of nuclear factor κB ligand) induced osteoclast formation in primary bone marrow-derived macrophages. SPA0355 also suppresses the activation of the MAPKs, Akt, and NF-κB pathways. Additionally, SPA0355 promotes osteoblast differentiation, increases alkaline phosphatase activity, and enhances mineral nodule formation. SPA0355 can protect ovariectomized mice from bone loss by stimulating osteoblast differentiation and inhibiting osteoclast resorption, making it useful for studying postmenopausal osteoporosis.
    SPA0355
  • HY-169792
    HPG1860 2226133-29-3 99.9%
    HPG1860 is an orally active, highly selective and potent FXR agonist, with an EC50 of 18 nM (FXR-luciferase reporter assay). HPG1860 has EC50 values >30.0 μM for TGR5 and 13 other related nuclear receptors (cAMP biological assay). HPG1860 can be used for the research of non-alcoholic steatohepatitis (NASH).
    HPG1860
  • HY-169859
    EP4 receptor antagonist 7 3035217-40-1 99.9%
    EP4 receptor antagonist 7 (Compound 14) is an antagonist of the prostaglandin E2 (PGE2) receptor subtype EP4 with an IC50 value of 1.1 nM. EP4 receptor antagonist 7 inhibits PGE2-induced β-arrestin recruitment in HEK293 cells with an IC50 value of 0.9 nM. EP4 receptor antagonist 7 decreases PGE2-induced expression of mRNA encoding IL-4, macrophage mannose receptor 1 (Mrc1), chitinase-like protein 3 (Chil3), chemokine (C-X-C) motif ligand 1 (Cxcl1), triggering receptor expressed on myeloid cells 2 (Trem2), and arginase-1 (Arg1), in RAW 264.7 macrophages. EP4 receptor antagonist 7 combined with an anti-PD-1 antibody inhibits tumor growth and increases infiltration of CD8+ T cells into tumors in a CT26 murine colon cancer model.
    EP4 receptor antagonist 7
  • HY-169981
    PDE4-IN-24 3087059-29-5 99.44%
    PDE4-IN-24 (compoud 14h) is a potent inhibitor of PDE4D with the IC50 of 0.57 nM and >4100-fold selectivity over other PDE families. PDE4-IN-24 plays an important role in inflammatory disease.
    PDE4-IN-24
  • HY-17042S
    Cetirizine-d4 1219803-84-5 99.10%
    Cetirizine-d4 is a deuterium labeled Cetirizine. Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response[1][2][3].
    Cetirizine-d4
  • HY-170522
    ISM012-042 2924181-80-4 98.69%
    ISM012-042 is an orally active PHD1 and PHD2 inhibitor with IC50 values of 1.9 and 2.5 nM, respectively. ISM012-042 (2.5 μM) can protect Caco-2 cells from DSS-induced barrier disruption. In lipopolysaccharide (LPS)-induced mouse bone marrow-derived dendritic cells (BMDC), ISM012-042 has anti-inflammatory effects and can dose-dependently reduce the expression of IL-12 subunit IL-12p35 and TNF. ISM012-042 restores intestinal barrier function and alleviates intestinal inflammation in various experimental colitis models. ISM012-042 can be used for intestinal mucosal repair and research into immune diseases.
    ISM012-042
  • HY-171012
    Clonixeril 21829-22-1 98%
    Clonixeril (NSC 335504) is a non-nucleotide hSTING modulator. Clonixeril has weak agonist activity at micromolar concentrations and results in antagonism of the hSTINGWT pathway at low femtomolar (10-15 M) and in some cases even attomolar (10-18 M) concentrations. Clonixeril reduces hSTING oligomerization at a concentration of 1 aM-1 pM.
    Clonixeril
  • HY-171128
    PTX-M 2130882-23-2 99.95%
    PTX-M is an oxidized metabolite of Pentoxifylline (HY-B0715). Pentoxifylline is a phosphodiesterase inhibitor that can be used for the study of peripheral vascular, inflammatory, and immune diseases.
    PTX-M
  • HY-171366
    lirucitinib 2458115-78-9 98.72%
    lirucitinib is a JAK inhibitor, and has antiinflammatory activity. lirucitinib inhibits various itch- and inflammation-inducing cytokines that depend on JAK1 enzyme activity, as well as allergy-related cytokines. lirucitinib can be used for the study of pruritic skin diseases
    lirucitinib
  • HY-171657
    4'-Acetoxy resveratrol 411233-11-9 99.90%
    4'-Acetoxy resveratrol is a Resveratrol (HY-16561) derivative. 4'-Acetoxy resveratrol upregulates gene expression of elastin, collagen types III and IV, superoxide dismutase (SOD), and catalase (CAT), while downregulating interleukins (IL-1A, IL-1R2, IL-6, IL-8) and cyclooxygenase-2 (COX-2) in human skin models. 4'-Acetoxy resveratrol can be used for skin reasearch.
    4'-Acetoxy resveratrol
  • HY-171804
    Linvemastat 2389060-50-6 98.30%
    Linvemastat (Compound FC-4) is an orally active MMP-12 inhibitor (IC50: < 10  nM) with high selectivity of MMP-1, -2, -3, -7, -9, -10 and -14. Linvemastat significantly attenuates lung fibrosis in Bleomycin (HY-108345) induced unilateral lung fibrosis mice model and potently reduces kidney damage, interstitial inflammation or fibrosis in kidney fibrosis model of unilateral ureteral occlusion. Linvemastat can be used for inflammatory diseases research, such as idiopathie pulmonary fibrosis (IPF), inflammatory bowel disease (IBD) and asthma.
    Linvemastat
  • HY-171878
    BI-4659 894784-05-5 99.78%
    BI-4659 is a TGFβRI and PDGFRα inhibitor with IC50 values of 19 nM and 99 nM, respectively. BI-4659 inhibits the kinase activities of TGFβRI and PDGFRα, blocks the downstream TGFβRI signaling pathway, and reduces the phosphorylation level of Smad2/3 without altering the expression of TGF-β1. BI-4659 is applicable to research related to pulmonary fibrosis, cancer, and renal ischemia-reperfusion injury.
    BI-4659
Cat. No. Product Name / Synonyms Application Reactivity